nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Mitomycin—stomach cancer	0.115	0.581	CbGbCtD
Carfilzomib—ABCB1—Irinotecan—stomach cancer	0.0295	0.149	CbGbCtD
Carfilzomib—ABCB1—Docetaxel—stomach cancer	0.0217	0.109	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—stomach cancer	0.0161	0.0815	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—stomach cancer	0.0156	0.0789	CbGbCtD
Carfilzomib—PSMB10—hematopoietic system—stomach cancer	0.0113	0.0715	CbGeAlD
Carfilzomib—PSMB10—lymphoid tissue—stomach cancer	0.00797	0.0503	CbGeAlD
Carfilzomib—PSMB10—digestive system—stomach cancer	0.00787	0.0497	CbGeAlD
Carfilzomib—PSMB10—endocrine gland—stomach cancer	0.0065	0.0411	CbGeAlD
Carfilzomib—PSMB8—pancreas—stomach cancer	0.00594	0.0375	CbGeAlD
Carfilzomib—PSMB10—liver—stomach cancer	0.00586	0.037	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—stomach cancer	0.00567	0.0358	CbGeAlD
Carfilzomib—PSMB1—hematopoietic system—stomach cancer	0.00563	0.0356	CbGeAlD
Carfilzomib—PSMB2—hematopoietic system—stomach cancer	0.00549	0.0347	CbGeAlD
Carfilzomib—PSMB5—pancreas—stomach cancer	0.00525	0.0331	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—stomach cancer	0.00496	0.0313	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—stomach cancer	0.00484	0.0306	CbGeAlD
Carfilzomib—PSMB8—bone marrow—stomach cancer	0.00468	0.0295	CbGeAlD
Carfilzomib—PSMB1—pancreas—stomach cancer	0.00458	0.029	CbGeAlD
Carfilzomib—PSMB10—lymph node—stomach cancer	0.0045	0.0284	CbGeAlD
Carfilzomib—PSMB2—pancreas—stomach cancer	0.00447	0.0283	CbGeAlD
Carfilzomib—PSMB5—bone marrow—stomach cancer	0.00413	0.0261	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—stomach cancer	0.00396	0.025	CbGeAlD
Carfilzomib—PSMB1—digestive system—stomach cancer	0.00392	0.0247	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—stomach cancer	0.00387	0.0244	CbGeAlD
Carfilzomib—PSMB2—digestive system—stomach cancer	0.00382	0.0241	CbGeAlD
Carfilzomib—PSMB8—liver—stomach cancer	0.00378	0.0239	CbGeAlD
Carfilzomib—PSMB1—bone marrow—stomach cancer	0.00361	0.0228	CbGeAlD
Carfilzomib—PSMB2—bone marrow—stomach cancer	0.00352	0.0222	CbGeAlD
Carfilzomib—PSMB5—liver—stomach cancer	0.00334	0.0211	CbGeAlD
Carfilzomib—PSMB1—endocrine gland—stomach cancer	0.00324	0.0204	CbGeAlD
Carfilzomib—PSMB2—endocrine gland—stomach cancer	0.00316	0.0199	CbGeAlD
Carfilzomib—PSMB1—liver—stomach cancer	0.00292	0.0184	CbGeAlD
Carfilzomib—PSMB8—lymph node—stomach cancer	0.0029	0.0183	CbGeAlD
Carfilzomib—PSMB2—liver—stomach cancer	0.00285	0.018	CbGeAlD
Carfilzomib—PSMB5—lymph node—stomach cancer	0.00256	0.0162	CbGeAlD
Carfilzomib—PSMB1—lymph node—stomach cancer	0.00224	0.0141	CbGeAlD
Carfilzomib—PSMB2—lymph node—stomach cancer	0.00218	0.0138	CbGeAlD
Carfilzomib—ABCB1—blood vessel—stomach cancer	0.00158	0.00995	CbGeAlD
Carfilzomib—Upper respiratory tract infection—Fluorouracil—stomach cancer	0.000876	0.00339	CcSEcCtD
Carfilzomib—Hepatic failure—Docetaxel—stomach cancer	0.000876	0.00339	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Docetaxel—stomach cancer	0.000868	0.00336	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Irinotecan—stomach cancer	0.000865	0.00335	CcSEcCtD
Carfilzomib—Renal failure—Irinotecan—stomach cancer	0.000862	0.00334	CcSEcCtD
Carfilzomib—Dizziness—Mitomycin—stomach cancer	0.000852	0.0033	CcSEcCtD
Carfilzomib—Hepatic failure—Capecitabine—stomach cancer	0.000848	0.00329	CcSEcCtD
Carfilzomib—Pneumonia—Fluorouracil—stomach cancer	0.000845	0.00327	CcSEcCtD
Carfilzomib—ABCB1—hematopoietic system—stomach cancer	0.000839	0.0053	CbGeAlD
Carfilzomib—Acute coronary syndrome—Fluorouracil—stomach cancer	0.000828	0.00321	CcSEcCtD
Carfilzomib—Renal failure acute—Capecitabine—stomach cancer	0.000825	0.0032	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fluorouracil—stomach cancer	0.000824	0.00319	CcSEcCtD
Carfilzomib—Vomiting—Mitomycin—stomach cancer	0.000819	0.00317	CcSEcCtD
Carfilzomib—Headache—Mitomycin—stomach cancer	0.000807	0.00313	CcSEcCtD
Carfilzomib—Hyponatraemia—Docetaxel—stomach cancer	0.00079	0.00306	CcSEcCtD
Carfilzomib—Pain in extremity—Docetaxel—stomach cancer	0.000787	0.00305	CcSEcCtD
Carfilzomib—ABCB1—epithelium—stomach cancer	0.000767	0.00485	CbGeAlD
Carfilzomib—Nausea—Mitomycin—stomach cancer	0.000765	0.00297	CcSEcCtD
Carfilzomib—Hyponatraemia—Capecitabine—stomach cancer	0.000765	0.00296	CcSEcCtD
Carfilzomib—Pain in extremity—Capecitabine—stomach cancer	0.000762	0.00295	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fluorouracil—stomach cancer	0.000751	0.00291	CcSEcCtD
Carfilzomib—Cardiac disorder—Irinotecan—stomach cancer	0.000731	0.00283	CcSEcCtD
Carfilzomib—Cardiac arrest—Capecitabine—stomach cancer	0.000725	0.00281	CcSEcCtD
Carfilzomib—Blood creatinine increased—Capecitabine—stomach cancer	0.000714	0.00277	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Docetaxel—stomach cancer	0.000709	0.00275	CcSEcCtD
Carfilzomib—Chills—Irinotecan—stomach cancer	0.000707	0.00274	CcSEcCtD
Carfilzomib—Hypokalaemia—Capecitabine—stomach cancer	0.000693	0.00269	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Capecitabine—stomach cancer	0.000686	0.00266	CcSEcCtD
Carfilzomib—ABCB1—pancreas—stomach cancer	0.000683	0.00432	CbGeAlD
Carfilzomib—Sepsis—Methotrexate—stomach cancer	0.000678	0.00263	CcSEcCtD
Carfilzomib—Back pain—Irinotecan—stomach cancer	0.000663	0.00257	CcSEcCtD
Carfilzomib—Muscle spasms—Irinotecan—stomach cancer	0.000659	0.00255	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—stomach cancer	0.000636	0.00246	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—stomach cancer	0.000635	0.00246	CcSEcCtD
Carfilzomib—Anaemia—Irinotecan—stomach cancer	0.000634	0.00246	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—stomach cancer	0.000631	0.00245	CcSEcCtD
Carfilzomib—Neutropenia—Capecitabine—stomach cancer	0.000616	0.00239	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—stomach cancer	0.000614	0.00238	CcSEcCtD
Carfilzomib—Leukopenia—Irinotecan—stomach cancer	0.000614	0.00238	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Capecitabine—stomach cancer	0.000612	0.00237	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—stomach cancer	0.00061	0.00236	CcSEcCtD
Carfilzomib—Anaemia—Fluorouracil—stomach cancer	0.000607	0.00235	CcSEcCtD
Carfilzomib—Cough—Irinotecan—stomach cancer	0.000598	0.00232	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—stomach cancer	0.000598	0.00232	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—stomach cancer	0.000596	0.00231	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—stomach cancer	0.000595	0.0023	CcSEcCtD
Carfilzomib—Hyperglycaemia—Capecitabine—stomach cancer	0.000594	0.0023	CcSEcCtD
Carfilzomib—Hypertension—Irinotecan—stomach cancer	0.000592	0.00229	CcSEcCtD
Carfilzomib—ABCB1—lymphoid tissue—stomach cancer	0.000591	0.00373	CbGeAlD
Carfilzomib—Hepatic failure—Epirubicin—stomach cancer	0.000591	0.00229	CcSEcCtD
Carfilzomib—Pneumonia—Capecitabine—stomach cancer	0.000591	0.00229	CcSEcCtD
Carfilzomib—Leukopenia—Fluorouracil—stomach cancer	0.000588	0.00228	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—stomach cancer	0.000587	0.00228	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—stomach cancer	0.000585	0.00227	CcSEcCtD
Carfilzomib—ABCB1—digestive system—stomach cancer	0.000584	0.00369	CbGeAlD
Carfilzomib—Acute coronary syndrome—Capecitabine—stomach cancer	0.000579	0.00224	CcSEcCtD
Carfilzomib—Renal failure—Capecitabine—stomach cancer	0.000577	0.00224	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Capecitabine—stomach cancer	0.000576	0.00223	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—stomach cancer	0.000575	0.00223	CcSEcCtD
Carfilzomib—Infection—Irinotecan—stomach cancer	0.000556	0.00215	CcSEcCtD
Carfilzomib—Thrombocytopenia—Irinotecan—stomach cancer	0.000548	0.00212	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—stomach cancer	0.000547	0.00212	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—stomach cancer	0.000542	0.0021	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—stomach cancer	0.000542	0.0021	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—stomach cancer	0.000538	0.0034	CbGeAlD
Carfilzomib—Oedema peripheral—Docetaxel—stomach cancer	0.000536	0.00208	CcSEcCtD
Carfilzomib—Anorexia—Irinotecan—stomach cancer	0.000533	0.00207	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—stomach cancer	0.000533	0.00207	CcSEcCtD
Carfilzomib—Infection—Fluorouracil—stomach cancer	0.000532	0.00206	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—stomach cancer	0.000532	0.00206	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—stomach cancer	0.000531	0.00206	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fluorouracil—stomach cancer	0.000525	0.00203	CcSEcCtD
Carfilzomib—Hypoaesthesia—Capecitabine—stomach cancer	0.000525	0.00203	CcSEcCtD
Carfilzomib—Oedema peripheral—Capecitabine—stomach cancer	0.000519	0.00201	CcSEcCtD
Carfilzomib—Anorexia—Fluorouracil—stomach cancer	0.000511	0.00198	CcSEcCtD
Carfilzomib—Insomnia—Irinotecan—stomach cancer	0.000506	0.00196	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—stomach cancer	0.000505	0.00196	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—stomach cancer	0.000505	0.00196	CcSEcCtD
Carfilzomib—Dyspnoea—Irinotecan—stomach cancer	0.000499	0.00193	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—stomach cancer	0.000497	0.00193	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—stomach cancer	0.000493	0.00191	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—stomach cancer	0.000491	0.0019	CcSEcCtD
Carfilzomib—Cardiac disorder—Capecitabine—stomach cancer	0.000489	0.0019	CcSEcCtD
Carfilzomib—Chills—Docetaxel—stomach cancer	0.000489	0.00189	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—stomach cancer	0.000488	0.00189	CcSEcCtD
Carfilzomib—Decreased appetite—Irinotecan—stomach cancer	0.000486	0.00188	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—stomach cancer	0.000485	0.00188	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—stomach cancer	0.000483	0.00187	CcSEcCtD
Carfilzomib—Fatigue—Irinotecan—stomach cancer	0.000482	0.00187	CcSEcCtD
Carfilzomib—ABCB1—endocrine gland—stomach cancer	0.000482	0.00305	CbGeAlD
Carfilzomib—Constipation—Irinotecan—stomach cancer	0.000479	0.00185	CcSEcCtD
Carfilzomib—Pain—Irinotecan—stomach cancer	0.000479	0.00185	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—stomach cancer	0.000478	0.00185	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—stomach cancer	0.000478	0.00185	CcSEcCtD
Carfilzomib—Chills—Capecitabine—stomach cancer	0.000473	0.00183	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—stomach cancer	0.000467	0.00181	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—stomach cancer	0.000466	0.00181	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—stomach cancer	0.00046	0.00178	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—stomach cancer	0.000458	0.00178	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—stomach cancer	0.000458	0.00178	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—stomach cancer	0.000458	0.00178	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—stomach cancer	0.000456	0.00177	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—stomach cancer	0.000456	0.00177	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—stomach cancer	0.000447	0.00173	CcSEcCtD
Carfilzomib—Back pain—Capecitabine—stomach cancer	0.000444	0.00172	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—stomach cancer	0.000442	0.00171	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—stomach cancer	0.000442	0.00171	CcSEcCtD
Carfilzomib—Muscle spasms—Capecitabine—stomach cancer	0.000441	0.00171	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—stomach cancer	0.00044	0.0017	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—stomach cancer	0.000438	0.0017	CcSEcCtD
Carfilzomib—ABCB1—liver—stomach cancer	0.000435	0.00275	CbGeAlD
Carfilzomib—Renal failure—Methotrexate—stomach cancer	0.00043	0.00166	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—stomach cancer	0.000429	0.00166	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—stomach cancer	0.000426	0.00165	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—stomach cancer	0.000424	0.00164	CcSEcCtD
Carfilzomib—Anaemia—Capecitabine—stomach cancer	0.000424	0.00164	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—stomach cancer	0.000424	0.00164	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—stomach cancer	0.000414	0.0016	CcSEcCtD
Carfilzomib—Cough—Docetaxel—stomach cancer	0.000414	0.0016	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—stomach cancer	0.000411	0.00159	CcSEcCtD
Carfilzomib—Leukopenia—Capecitabine—stomach cancer	0.000411	0.00159	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—stomach cancer	0.000409	0.00159	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—stomach cancer	0.000404	0.00156	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—stomach cancer	0.000402	0.00156	CcSEcCtD
Carfilzomib—Asthenia—Irinotecan—stomach cancer	0.000401	0.00156	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—stomach cancer	0.000401	0.00155	CcSEcCtD
Carfilzomib—Cough—Capecitabine—stomach cancer	0.0004	0.00155	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—stomach cancer	0.000397	0.00154	CcSEcCtD
Carfilzomib—Hypertension—Capecitabine—stomach cancer	0.000396	0.00154	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—stomach cancer	0.000395	0.00153	CcSEcCtD
Carfilzomib—Arthralgia—Capecitabine—stomach cancer	0.000391	0.00151	CcSEcCtD
Carfilzomib—Infection—Docetaxel—stomach cancer	0.000384	0.00149	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—stomach cancer	0.000383	0.00148	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—stomach cancer	0.000383	0.00148	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—stomach cancer	0.000381	0.00148	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—stomach cancer	0.000379	0.00147	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—stomach cancer	0.000372	0.00144	CcSEcCtD
Carfilzomib—Infection—Capecitabine—stomach cancer	0.000372	0.00144	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—stomach cancer	0.000371	0.00144	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—stomach cancer	0.00037	0.00143	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—stomach cancer	0.000369	0.00143	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—stomach cancer	0.000367	0.00142	CcSEcCtD
Carfilzomib—Thrombocytopenia—Capecitabine—stomach cancer	0.000367	0.00142	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—stomach cancer	0.000365	0.00142	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—stomach cancer	0.000364	0.00141	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—stomach cancer	0.000362	0.0014	CcSEcCtD
Carfilzomib—Anorexia—Capecitabine—stomach cancer	0.000357	0.00138	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—stomach cancer	0.000356	0.00138	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—stomach cancer	0.000354	0.00137	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000352	0.00137	CcSEcCtD
Carfilzomib—Chills—Methotrexate—stomach cancer	0.000352	0.00136	CcSEcCtD
Carfilzomib—Headache—Irinotecan—stomach cancer	0.000351	0.00136	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—stomach cancer	0.00035	0.00136	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—stomach cancer	0.000345	0.00134	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000341	0.00132	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—stomach cancer	0.000341	0.00132	CcSEcCtD
Carfilzomib—Vomiting—Fluorouracil—stomach cancer	0.000341	0.00132	CcSEcCtD
Carfilzomib—Insomnia—Capecitabine—stomach cancer	0.000339	0.00131	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—stomach cancer	0.000338	0.00131	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—stomach cancer	0.000336	0.0013	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—stomach cancer	0.000336	0.0013	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—stomach cancer	0.000335	0.0013	CcSEcCtD
Carfilzomib—Dyspnoea—Capecitabine—stomach cancer	0.000334	0.00129	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—stomach cancer	0.000333	0.00129	CcSEcCtD
Carfilzomib—ABCB1—lymph node—stomach cancer	0.000333	0.00211	CbGeAlD
Carfilzomib—Nausea—Irinotecan—stomach cancer	0.000332	0.00129	CcSEcCtD
Carfilzomib—Pain—Docetaxel—stomach cancer	0.000331	0.00128	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—stomach cancer	0.000331	0.00128	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—stomach cancer	0.00033	0.00128	CcSEcCtD
Carfilzomib—Chills—Epirubicin—stomach cancer	0.00033	0.00128	CcSEcCtD
Carfilzomib—Decreased appetite—Capecitabine—stomach cancer	0.000326	0.00126	CcSEcCtD
Carfilzomib—Fatigue—Capecitabine—stomach cancer	0.000323	0.00125	CcSEcCtD
Carfilzomib—Pain—Capecitabine—stomach cancer	0.00032	0.00124	CcSEcCtD
Carfilzomib—Constipation—Capecitabine—stomach cancer	0.00032	0.00124	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—stomach cancer	0.000318	0.00123	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—stomach cancer	0.000316	0.00122	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—stomach cancer	0.000315	0.00122	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—stomach cancer	0.000309	0.0012	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—stomach cancer	0.000307	0.00119	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—stomach cancer	0.000306	0.00118	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—stomach cancer	0.000306	0.00118	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—stomach cancer	0.000305	0.00118	CcSEcCtD
Carfilzomib—Cough—Methotrexate—stomach cancer	0.000298	0.00116	CcSEcCtD
Carfilzomib—Body temperature increased—Capecitabine—stomach cancer	0.000296	0.00115	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—stomach cancer	0.000295	0.00114	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—stomach cancer	0.000291	0.00113	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—stomach cancer	0.000286	0.00111	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—stomach cancer	0.000286	0.00111	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—stomach cancer	0.000284	0.0011	CcSEcCtD
Carfilzomib—Cough—Epirubicin—stomach cancer	0.000279	0.00108	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—stomach cancer	0.000278	0.00108	CcSEcCtD
Carfilzomib—Infection—Methotrexate—stomach cancer	0.000277	0.00107	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—stomach cancer	0.000276	0.00107	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—stomach cancer	0.000273	0.00106	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—stomach cancer	0.000273	0.00106	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—stomach cancer	0.000272	0.00105	CcSEcCtD
Carfilzomib—Asthenia—Capecitabine—stomach cancer	0.000269	0.00104	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—stomach cancer	0.000266	0.00103	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—stomach cancer	0.000265	0.00103	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—stomach cancer	0.000265	0.00103	CcSEcCtD
Carfilzomib—Infection—Epirubicin—stomach cancer	0.000259	0.001	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—stomach cancer	0.000258	0.001	CcSEcCtD
Carfilzomib—Diarrhoea—Capecitabine—stomach cancer	0.000256	0.000993	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—stomach cancer	0.000256	0.000991	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—stomach cancer	0.000255	0.00099	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—stomach cancer	0.000255	0.00099	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000254	0.000984	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—stomach cancer	0.000252	0.000977	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—stomach cancer	0.000252	0.000976	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—stomach cancer	0.000249	0.000964	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—stomach cancer	0.000249	0.000963	CcSEcCtD
Carfilzomib—Dizziness—Capecitabine—stomach cancer	0.000248	0.00096	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—stomach cancer	0.000246	0.000953	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—stomach cancer	0.000242	0.000939	CcSEcCtD
Carfilzomib—Headache—Docetaxel—stomach cancer	0.000242	0.000939	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—stomach cancer	0.00024	0.000931	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—stomach cancer	0.00024	0.000929	CcSEcCtD
Carfilzomib—Pain—Methotrexate—stomach cancer	0.000238	0.000924	CcSEcCtD
Carfilzomib—Vomiting—Capecitabine—stomach cancer	0.000238	0.000923	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000238	0.000921	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—stomach cancer	0.000236	0.000916	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—stomach cancer	0.000236	0.000914	CcSEcCtD
Carfilzomib—Headache—Capecitabine—stomach cancer	0.000235	0.000909	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—stomach cancer	0.000233	0.000901	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—stomach cancer	0.00023	0.000892	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—stomach cancer	0.00023	0.00089	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—stomach cancer	0.000227	0.000879	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—stomach cancer	0.000225	0.000872	CcSEcCtD
Carfilzomib—Pain—Epirubicin—stomach cancer	0.000223	0.000865	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—stomach cancer	0.000223	0.000865	CcSEcCtD
Carfilzomib—Nausea—Capecitabine—stomach cancer	0.000222	0.000862	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—stomach cancer	0.00022	0.000854	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.00022	0.000852	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—stomach cancer	0.000218	0.000846	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—stomach cancer	0.000215	0.000834	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—stomach cancer	0.00021	0.000813	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—stomach cancer	0.000208	0.000806	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—stomach cancer	0.000206	0.0008	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—stomach cancer	0.000206	0.0008	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—stomach cancer	0.000206	0.000799	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—stomach cancer	0.0002	0.000775	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—stomach cancer	0.000191	0.000739	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—stomach cancer	0.000191	0.000739	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—stomach cancer	0.000187	0.000725	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—stomach cancer	0.000184	0.000714	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—stomach cancer	0.000179	0.000692	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—stomach cancer	0.000177	0.000687	CcSEcCtD
Carfilzomib—Headache—Methotrexate—stomach cancer	0.000175	0.000677	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—stomach cancer	0.000173	0.000671	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—stomach cancer	0.000173	0.000669	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—stomach cancer	0.000166	0.000643	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—stomach cancer	0.000166	0.000642	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—stomach cancer	0.000165	0.00064	CcSEcCtD
Carfilzomib—Headache—Epirubicin—stomach cancer	0.000163	0.000633	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—stomach cancer	0.00016	0.000619	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—stomach cancer	0.000155	0.0006	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—stomach cancer	0.000153	0.000595	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—stomach cancer	0.000151	0.000586	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—stomach cancer	0.000143	0.000556	CcSEcCtD
Carfilzomib—PSMB1—Disease—CDKN1A—stomach cancer	1.59e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CDKN1A—stomach cancer	1.59e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1B—stomach cancer	1.58e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CDKN1A—stomach cancer	1.56e-05	4.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6R—stomach cancer	1.55e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6R—stomach cancer	1.55e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6R—stomach cancer	1.55e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALDOB—stomach cancer	1.54e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—stomach cancer	1.53e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—stomach cancer	1.53e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—stomach cancer	1.53e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6R—stomach cancer	1.53e-05	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—stomach cancer	1.52e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—stomach cancer	1.52e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—stomach cancer	1.52e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—stomach cancer	1.52e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—JUN—stomach cancer	1.51e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—stomach cancer	1.51e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—stomach cancer	1.51e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—JUN—stomach cancer	1.5e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—stomach cancer	1.5e-05	3.89e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—stomach cancer	1.48e-05	3.84e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—stomach cancer	1.48e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—stomach cancer	1.47e-05	3.82e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—stomach cancer	1.47e-05	3.82e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—stomach cancer	1.47e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—stomach cancer	1.47e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CDKN1A—stomach cancer	1.47e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK3—stomach cancer	1.46e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK3—stomach cancer	1.46e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK3—stomach cancer	1.46e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—stomach cancer	1.46e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1A—stomach cancer	1.46e-05	3.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MAPK3—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MAPK3—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MAPK3—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—stomach cancer	1.46e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK3—stomach cancer	1.44e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MAPK3—stomach cancer	1.44e-05	3.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—stomach cancer	1.44e-05	3.72e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALOX5—stomach cancer	1.43e-05	3.71e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—stomach cancer	1.43e-05	3.71e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK8—stomach cancer	1.43e-05	3.71e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK8—stomach cancer	1.42e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—stomach cancer	1.42e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—stomach cancer	1.42e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—stomach cancer	1.42e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—stomach cancer	1.42e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—stomach cancer	1.42e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—stomach cancer	1.42e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—stomach cancer	1.41e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DPYD—stomach cancer	1.41e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—stomach cancer	1.41e-05	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RHOA—stomach cancer	1.4e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RHOA—stomach cancer	1.4e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RHOA—stomach cancer	1.4e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—stomach cancer	1.4e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—stomach cancer	1.4e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK1—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK1—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK1—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—stomach cancer	1.39e-05	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—stomach cancer	1.39e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—stomach cancer	1.39e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—stomach cancer	1.39e-05	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RHOA—stomach cancer	1.38e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOA1—stomach cancer	1.38e-05	3.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK1—stomach cancer	1.37e-05	3.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—stomach cancer	1.37e-05	3.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—stomach cancer	1.37e-05	3.55e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—stomach cancer	1.36e-05	3.54e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—stomach cancer	1.36e-05	3.52e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—stomach cancer	1.35e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—stomach cancer	1.35e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—stomach cancer	1.35e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—stomach cancer	1.33e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—stomach cancer	1.32e-05	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—stomach cancer	1.32e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—stomach cancer	1.32e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—stomach cancer	1.32e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—stomach cancer	1.32e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—stomach cancer	1.32e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—stomach cancer	1.32e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—stomach cancer	1.31e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—stomach cancer	1.31e-05	3.39e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—stomach cancer	1.3e-05	3.39e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—stomach cancer	1.3e-05	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—stomach cancer	1.3e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—stomach cancer	1.3e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—stomach cancer	1.3e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—stomach cancer	1.3e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—stomach cancer	1.3e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—stomach cancer	1.3e-05	3.36e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK1—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK1—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK1—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—stomach cancer	1.29e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—stomach cancer	1.28e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK1—stomach cancer	1.27e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—stomach cancer	1.27e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—stomach cancer	1.25e-05	3.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—stomach cancer	1.25e-05	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—stomach cancer	1.24e-05	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—stomach cancer	1.23e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—stomach cancer	1.23e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—stomach cancer	1.23e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—stomach cancer	1.23e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2A6—stomach cancer	1.23e-05	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—stomach cancer	1.23e-05	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—stomach cancer	1.22e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—stomach cancer	1.22e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—stomach cancer	1.22e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—stomach cancer	1.22e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—stomach cancer	1.22e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—stomach cancer	1.21e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—stomach cancer	1.21e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—stomach cancer	1.21e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—stomach cancer	1.21e-05	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—stomach cancer	1.2e-05	3.12e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—stomach cancer	1.2e-05	3.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—stomach cancer	1.2e-05	3.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—stomach cancer	1.2e-05	3.11e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C3—stomach cancer	1.2e-05	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—stomach cancer	1.19e-05	3.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK1—stomach cancer	1.19e-05	3.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—stomach cancer	1.19e-05	3.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—stomach cancer	1.19e-05	3.08e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK1—stomach cancer	1.18e-05	3.07e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—stomach cancer	1.18e-05	3.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO1—stomach cancer	1.17e-05	3.03e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—stomach cancer	1.15e-05	2.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—stomach cancer	1.15e-05	2.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—stomach cancer	1.15e-05	2.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—stomach cancer	1.15e-05	2.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—stomach cancer	1.15e-05	2.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—stomach cancer	1.15e-05	2.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—stomach cancer	1.13e-05	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—stomach cancer	1.13e-05	2.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—stomach cancer	1.12e-05	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—stomach cancer	1.12e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—stomach cancer	1.11e-05	2.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—stomach cancer	1.11e-05	2.89e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—stomach cancer	1.11e-05	2.89e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—stomach cancer	1.11e-05	2.88e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—stomach cancer	1.11e-05	2.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—stomach cancer	1.11e-05	2.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—stomach cancer	1.1e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—stomach cancer	1.1e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—stomach cancer	1.1e-05	2.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—stomach cancer	1.1e-05	2.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	1.09e-05	2.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—stomach cancer	1.08e-05	2.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—stomach cancer	1.08e-05	2.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—stomach cancer	1.08e-05	2.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—stomach cancer	1.07e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—stomach cancer	1.07e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—stomach cancer	1.07e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—stomach cancer	1.07e-05	2.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—stomach cancer	1.06e-05	2.74e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD44—stomach cancer	1.03e-05	2.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—stomach cancer	1.03e-05	2.68e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—stomach cancer	1.03e-05	2.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—stomach cancer	1.03e-05	2.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—stomach cancer	1.03e-05	2.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—stomach cancer	1.03e-05	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—stomach cancer	1.02e-05	2.64e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—stomach cancer	1e-05	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—stomach cancer	1e-05	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—stomach cancer	1e-05	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—stomach cancer	9.98e-06	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—stomach cancer	9.93e-06	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—stomach cancer	9.91e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—stomach cancer	9.91e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—stomach cancer	9.91e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—stomach cancer	9.89e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—stomach cancer	9.89e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—stomach cancer	9.89e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—stomach cancer	9.87e-06	2.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—stomach cancer	9.77e-06	2.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—stomach cancer	9.75e-06	2.53e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—stomach cancer	9.55e-06	2.48e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—stomach cancer	9.5e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—stomach cancer	9.47e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—stomach cancer	9.47e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—stomach cancer	9.47e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—stomach cancer	9.35e-06	2.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—stomach cancer	9.35e-06	2.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—stomach cancer	9.35e-06	2.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—stomach cancer	9.34e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—stomach cancer	9.22e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—stomach cancer	9.21e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—stomach cancer	9.21e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—stomach cancer	9.21e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—stomach cancer	9.14e-06	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—stomach cancer	9.09e-06	2.36e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—stomach cancer	9.08e-06	2.36e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK1—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK1—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK1—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—stomach cancer	9.01e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK1—stomach cancer	8.88e-06	2.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—stomach cancer	8.88e-06	2.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPP2R1A—stomach cancer	8.8e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—stomach cancer	8.63e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—stomach cancer	8.51e-06	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—stomach cancer	8.51e-06	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—stomach cancer	8.51e-06	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—stomach cancer	8.51e-06	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—stomach cancer	8.39e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—stomach cancer	8.02e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—stomach cancer	7.93e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—stomach cancer	7.82e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—stomach cancer	7.82e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—stomach cancer	7.82e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—stomach cancer	7.71e-06	2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—stomach cancer	7.56e-06	1.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—stomach cancer	7.56e-06	1.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—stomach cancer	7.56e-06	1.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—stomach cancer	7.46e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—stomach cancer	7.46e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—stomach cancer	7.23e-06	1.88e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—stomach cancer	7.23e-06	1.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—stomach cancer	7.23e-06	1.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—stomach cancer	7.13e-06	1.85e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—stomach cancer	7.01e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—stomach cancer	6.92e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—stomach cancer	6.92e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—stomach cancer	6.92e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—stomach cancer	6.83e-06	1.77e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—stomach cancer	6.47e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA1—stomach cancer	6.45e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—stomach cancer	5.68e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—stomach cancer	5.11e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—stomach cancer	4.89e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—stomach cancer	4.47e-06	1.16e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—stomach cancer	2.75e-06	7.14e-06	CbGpPWpGaD
